sunepitron has been researched along with ipsapirone in 1 studies
| Studies (sunepitron) | Trials (sunepitron) | Recent Studies (post-2010) (sunepitron) | Studies (ipsapirone) | Trials (ipsapirone) | Recent Studies (post-2010) (ipsapirone) |
|---|---|---|---|---|---|
| 10 | 0 | 1 | 373 | 58 | 14 |
| Protein | Taxonomy | sunepitron (IC50) | ipsapirone (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 10 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 1 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 10 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 1 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 1 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.0082 | |
| D(4) dopamine receptor | Homo sapiens (human) | 1.8 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.5 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 10 | |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.5 | |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | 0.5 | |
| D(3) dopamine receptor | Homo sapiens (human) | 1.2 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 2.9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Becker, OM; Chen, D; Cheruku, S; Dhanoa, DS; Fichman, M; Heifetz, A; Kauffman, M; Marantz, Y; Mohanty, P; Noiman, S; Nudelman, R; Shacham, S; Sharadendu, A | 1 |
1 other study(ies) available for sunepitron and ipsapirone
| Article | Year |
|---|---|
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Binding, Competitive; Biological Availability; Cell Line; Clinical Trials, Phase I as Topic; Dogs; Drug Design; Half-Life; Humans; In Vitro Techniques; Male; Mice; Microsomes, Liver; Models, Molecular; Patch-Clamp Techniques; Piperazines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Serotonin 5-HT1 Receptor Agonists; Structure-Activity Relationship; Sulfonamides | 2006 |